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doi:10.1016/j.asjsur.2012.04.024Summary Background/Objective: Recently, endoscopic and radiological procedures for
various symptoms related to cirrhosis have improved. Thus, the role of Hassab’s operation
(gastroesophageal decongestion and splenectomy) has changed for cirrhotic patients.
Methods: Hassab’s operation was performed on patients who had gastroesophageal varices
that were difficult to control with balloon occluded retrograde transvenous obliteration or
an endoscopic procedure, or had hypersplenism. Thirteen consecutive patients underwent this
operation, and the outcomes of all patients were reviewed retrospectively.
Results: There was no operative morbidity or rebleeding varices. In the preoperative endo-
scopic injection sclerotherapy treated group (nZ 6), only one patient (16.7%) developed
recurrent varices. Mean platelet counts were significantly higher 6 months after surgery
(201 65 103/mm3) than preoperatively (64 54 103/mm3). In patients with hepatocel-
lular carcinoma, percutaneous therapies, such as radio frequency ablation, were safely per-
formed with adequate therapeutic effect. Interferon therapy was given to patients with
hepatitis C virus (HCV)-related cirrhosis without interruption.
Conclusion: Hassab’s operation is a satisfactory approach to controlling varices, especially
when combined with preoperative endoscopic treatment. Platelet counts were significantly
higher after surgery. This therapy was important for cirrhotic patients contraindicated for livert of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science,
chi, Kanazawa, Ishikawa 920-8641, Japan.
l.com (H. Hayashi).
n Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
58 H. Hayashi et al.Table 1 Summary of the clinica
Case Sex Age Preo
Tx. f
1 M 41 EVL
2 F 57 None
3 M 52 None
4 M 57 None
5 M 49 EVL
6 M 66 None
7 M 38 EIS
8 M 45 EVL
9 F 62 EIS
10 M 60 EIS
11 F 46 None
12 M 62 EVL
13 M 50 EVL
EISZ endoscopic injection scleroth
n.a.Z not applicable; PVTZ portal
a Varices according to: The genera
(2004).transplantation in that they could continue their therapy for hepatocellular carcinoma (HCC)
and HCV as needed.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Bleeding of gastroesophageal varices is the most hazardous
complication of portal hypertension, with a high mortality
rate.1 Endoscopic procedures such as endoscopic injection
sclerotherapy (EIS) and endoscopic variceal band ligation
(EVL) are reasonably effective to control varices.2 Also,
radiologic procedures such as transjugular intrahepatic
portsystemic shunt (TIPS) and balloon occluded retrograde
transvenous obliteration (B-RTO) have satisfactory results
in controlling these varices.3,4
Similarly, hypersplenism prevents safe application of the
treatments for hepatitis C and hepatocellular carcinoma
(HCC) because of thrombocytopenia. Recently, the useful-
ness of partial splenic embolization (PSE) for hypersplenism
was reported.5 The usefulness of these procedures has
changed the therapeutic modality for gastroesophageal
varices and/or hypersplenism from surgical to endoscopic or
radiological. Thus, Hassab’s operation, which involves
devascularization of perigastroesophageal vessels and sple-
nectomy, has a new role as a procedure for cirrhotic patients.
The surgical procedure is very important for cirrhotic patients
as it treats several pathological processes caused by liver
cirrhosis. In this study, the usefulness of Hassab’s operation
for cirrhotic patients was examined retrospectively.
2. Patients and methods
Our indications for Hassab’s operation include gastro-
esophageal varices that are difficult to control withl data of all patients.
perative
or varices
Preoperative
EVa GV
& EIS F1 RC2 (e
F2 RC2 F3
F2 RC2 F1
F2 RC1 (e
F3 RC2 F3
F3 RC2 F2
F2 RC0 (e
F2 RC2 (e
F3 RC3 F3
F1 RC0 F4
F2 RC2 F2
& EIS F1 RC1 F1
& EIS F1 RC2 (e
erapy; EVZ esophageal varices;
vein thrombosis; TxZ therapy.
l rules for recording endoscopic firadiological and/or endoscopic procedures because of
repeated recurrence, or thrombocytopenia (platelets count
under 80 103/mm3) with gastroesophageal varices due to
hypersplenism related to cirrhosis. Patients with uncon-
trollable bleeding from gastroesophageal varices were
contraindicated. We used the surgical procedure of Has-
sab’s operation that has been described previously without
any modifications.6 Thirteen consecutive patients
(male:femaleZ 10:3) with a mean age of 52.7 (range,
38e66) years underwent Hassab’s operation during the
period from January 2004 to December 2008. The etiologies
of liver cirrhosis were hepatitis C virus (HCV) in eight
patients, hepatitis B virus (HBV) in two patients, idiopathic
portal hypertension in two patients, and alcoholic cirrhosis
in one patient. Preoperative therapies for gastroesophageal
varices were EIS combined with EVL in three patients, EIS
only in three patients, EVL only in two patients, and not
treated by an endoscopic procedure preoperatively in five
patients (Table 1). There were no perioperative hospital
deaths during this period. Endoscopic findings were based
on the general rules established by the Japanese Research
Society for Portal Hypertension.7 According to the rules,
the esophageal varices were classified into three grades: F1
(small, straight); F2 (moderate sized, tortuous); and F3
(large sized, nodular). The red color signs were defined into
four grades: RC0, RC1 (limited), RC2, and RC3 (circular,
many). Preoperative endoscopic examination and classifi-
cation according to this rule was performed in all cases.
Postoperative follow-up of gastroesophageal varices was
performed by annual endoscopic examination. Our criteria
for postoperative recurrent varices are greater than F2- orPostoperative Additional
treatment
Operative
morbidity
a EVa GVa
) F2 RC0 (e) (e) PVT
RC1 n.a. n.a. (e) (e)
RC0 F1 RC1 F1 RC0 (e) PVT, Ileus
) F2 RC1 (e) EVL PVT
RC0 F2 RC1 F1 RC0 (e) (e)
RC1 F2 RC0 (e) (e) (e)
) F1 RC0 (e) (e) (e)
) n.a. n.a. (e) (e)
RC0 F1 RC0 (e) (e) PVT
RC0 F1 RC0 F1 RC0 (e) (e)
RC0 F1 RC1 F1 RC0 (e) PVT
RC0 n.a. n.a. (e) PVT
) F1 RC1 (e) (e) (e)
EVLZ endoscopic variceal band ligation; GVZ gastric varices;
ndings of the Japanese Research Society for Portal Hypertension
Figure 2 Changes in serum albumin after Hassab’s opera-
tion. The serum albumin level was significantly lower than the
preoperative serum albumin for 2 weeks after surgery
*(p< 0.05).
Recent role of Hassab’s operation 59RC-positive cases. Written informed consent was obtained
from all participating patients. In the statistical analysis,
values are expressed as means standard deviation (SD).
The significance of the differences obtained was tested
using the ManneWhitney U-test. Differences were consid-
ered statistically significant at a level of p< 0.05.
3. Results
3.1. Change in hepatic reserve
According to the ChildePugh classification of functional
status for liver disease, nine patients were class A and four
patients were class B, preoperatively.8 Six months post-
operatively, the patients’ ChildePugh classifications were
unchanged. The total bilirubin level was 1.3 0.4 mg/dL,
and the serum albumin level was 3.5 0.5 g/dL, preoper-
atively. Six months after the operation, the total bilirubin
level was 1.0 0.5 mg/dL, and the serum albumin level was
3.7 0.5 g/dL (Figs. 1 and 2).
3.2. Operative time and blood loss
The time required for operation was 361 78 minutes. The
blood loss was 985 776 mL. The weight of the spleen was
665 409 g.
3.3. Therapeutic effect for varices
The mean duration of follow-up was 37.9 months. Of the 13
patients, three patients rejected postoperative endoscopic
follow-up. The variceal rebleeding rate was 0%. Only one
patient received additional endoscopic treatment (EVL) for
varices during the postoperative period. Six patients
developed recurrent varices after surgery. Of the six
patients who were treated with EIS preoperatively, only
one developed recurrent varices.Figure 1 Changes in serum bilirubin after Hassab’s opera-
tion. The serum bilirubin level was significantly lower than the
preoperative serum bilirubin for 2 weeks to 1 month after
surgery *(p< 0.05).3.4. Change in platelet counts
The postoperative platelet counts were significantly higher
than the preoperative platelets counts for 2 weeks to 6
months after surgery. The preoperative platelet count was
64 54 103/mm3. Six months after surgery, the platelet
count was 201 65 103/mm3 (Fig. 3).3.5. Operative morbidity and postoperative
hospital stay
There were no episodes of decompensated liver dysfunc-
tion, such as increased ascites or encephalopathy. Asymp-
tomatic portal vein thrombosis arising from the stump ofFigure 3 Changes in platelets counts after Hassab’s opera-
tion. The platelet counts were significantly higher than the
preoperative platelets counts for 2 weeks to 6 months after
surgery *(p< 0.05).
60 H. Hayashi et al.the splenic vein, which was graded as Grade 1 according to
the classification of Yerdel et al, occurred in six patients,
and ileus occurred in one patient.9 These complications
were all successfully treated with medication. Post-
operative hospital stay was 30.2 8.3 days.
3.6. Postoperative therapy for HCC
In three patients, HCC was found at operation. All lesions
were successfully treated with radiofrequency ablation
(RFA) or percutaneous ethanol injection therapy without
any complications.
3.7. Postoperative therapy for HCV
In four of eight HCV-positive patients, antiviral therapy was
performed using peginterferon plus ribavirin. No patients
were withdrawn from therapy due to thrombocytopenia
and leukocytopenia.
4. Discussion
The development of endoscopic therapy affects the
management of gastroesophageal varices, and many cases
have been treated with EIS and/or EVL.2 Interventional
radiology (IVR) for these patients has also improved. Thus,
symptoms such as gastric varices were treated by IVR, for
example, B-RTO and TIPS.3e5,10 Therefore, the role of
Hassab’s operation has recently changed from devascula-
rization itself to controlling various clinical settings due to
liver cirrhosis. In fact, some cases are resistant to or
recurrent after endoscopic or interventional therapy.4,11
Furthermore, it is reasonable to control gastroesophageal
varices using a combination of endoscopic, interventional,
and surgical procedures. Thus, the indications for Hassab’s
surgery at our institute have changed to include patients
who were contraindicated for liver transplantation due to
social and/or medical reasons with gastroesophageal vari-
ces that are difficult to control with IVR or an endoscopic
procedure, and those who have thrombocytopenia owing to
hypersplenism complicated by gastroesophageal varices.
In the present series, no patient had postoperative var-
iceal bleeding, but the variceal recurrence rate was high
(46.2%). However, in the subgroup of patients treated
preoperatively with EIS, only one patient (16.7%) developed
recurrent varices. These data support the use of combina-
tion therapy involving Hassab’s operation and EIS.12 Unlike
the SugiuraeFutagawa procedure, Hassab’s operation
devascularizes only the extramural vessels; intramural
vessels are not treated.13 Thus, EIS is needed for emboli-
zation of the intramural vessels and venous network. This
combination therapy was reasonable and effective. The
concept of the simultaneous combination of Hassab’s and
EIS therapy has been reported previously, but there was
operative mortality.14 The reason for the operative
mortality was thought to have been the compromised
nature of cirrhotic patients. Thus, two-stage therapy
involving the combination of preoperative EIS and Hassab’s
operation is better because of its safety and effectiveness.
The increase in the platelet count postsplenectomy has
practical benefit for patients undergoing interferon therapyfor hepatitis C virus and percutaneous radio frequency
ablation (RFA) for HCC. The usefulness of PSE in such situ-
ations has been reported, but the quantitative evaluation
of embolized volume during the procedure is still diffi-
cult.5,15 An important limitation of excessive embolization
is a high incidence of splenic abscess.16,17 Furthermore, the
risk of insufficient embolization as a result of attempting to
avoid excessive embolization exists. In our experience with
patients after PSE, splenectomy is difficult, because of
strong adhesions between the spleen and peritoneum
caused by inflammatory changes owing to PSE itself. Thus,
PSE is not performed in our institute. Our main therapy for
thrombocytopenia is splenectomy, including Hassab’s
operation. However, splenectomy is more invasive than
PSE, thus, the introduction of a less invasive surgical
approach, such as a laparoscopic procedure, is preferable
for cirrhotic patients.18
The occurrence of portal vein thrombosis was much
higher in the present study than in previous series.19,20 This
may be caused by our postoperative protocol to take
contrast enhanced CT to evaluate postoperative changes of
the surgical site and detect asymptomatic portal vein
thrombosis about 7e10 days after surgery. Thus, we had no
cases with symptomatic portal vein thrombosis, such as
massive ascites or gastrointestinal bleeding. Our protocols
for anticoagulation therapy immediately after operation
are systemic heparinization and replacement antithrombin
three to keep its activity above 80% starting from about the
3rd postoperative day. If portal vein thrombosis was seen on
contrast-enhanced CT, the heparin dosage was increased to
attain an activated partial thromboplastin time (APTT)
about two times longer than the normal range. After con-
firming the contraction of the thrombus, warfarin was
started to maintain the prothrombin timeeinternational
normalized ratio (PTeINR) at about two. This anti-
coagulation therapy is performed under hospitalization,
and affects the length of the hospital stay. Thus, our result
suggests that more safe and effective anticoagulation is
needed to manage these patients.
Postoperative changes in hepatic reserve after Hassab’s
operation were recently reported to include changes in
hepatic hemodynamic status that had a beneficial effect on
hepatic functional reserve.21 The details of the mechanisms
of liver regeneration after splenectomy have been reported
in a cirrhotic rat model.22,23 However, in the present series,
immediately after operation, hepatic functional reserve
deteriorated according to the ChildePugh classification,
and no definite change compared with the preoperative
status was observed 6 months postoperatively. These
exacerbations of hepatic reserve are suspected to be
caused by surgical stress and the time lag of the recovering
cirrhotic liver itself. The cause of the deterioration of
albumin is also suspected to be surgical stress. However,
the reasons for the postoperative change of bilirubin were
unexplained. Furthermore, the detailed mechanisms of the
beneficial effect of this procedure in humans are still
unclear. Thus, further investigations are needed.
In conclusion, Hassab’s operation is still meaningful, not
only for controlling gastroesophageal varices, but also to
treat some conditions related to cirrhosis for the patients
contraindicated for liver transplantation. In our institute,
asymptomatic portal vein thrombosis occurred at a high
Recent role of Hassab’s operation 61rate, but combination therapy with EIS was effective to
control varices. Studies involving more patients and more
detailed research, especially by hepatic reserve, are
needed for definite conclusions.
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